President Donald Trump’s new executive order promises to advance research on menopause, endometriosis, heart disease and other conditions affecting millions of American women. Championed by First Lady Melania Trump, the initiative creates a new division at the National Institutes of Health. But it also repeals two Biden-era measures and includes no specific new funding commitment, raising questions about what the policy will actually deliver.
First Lady Melania Trump has stepped into the national spotlight with an ambitious new women’s health initiative, as President Donald Trump moves to reorganize federal research efforts just two weeks before the November midterm elections.
On October 19, the president signed an executive order titled Advancing Women’s Health to Improve Outcomes in All Phases of Life, establishing a new Women’s Health Division within the National Institutes of Health (NIH) and a White House task force to coordinate research, prevention and treatment.
The administration says the plan will accelerate medical breakthroughs for conditions that have historically received insufficient scientific attention.
Yet the order also revokes two initiatives introduced under former President Joe Biden, whose administration had made women’s health research a national priority. And unlike the nearly $1 billion in funding previously announced under Biden, the new directive does not specify an additional investment.
The contrast raises a central question: can the Trump administration expand women’s health research while reversing its predecessor’s initiatives and pursuing broader changes to federal science funding?
Melania Trump Makes Menopause and Women’s Health a White House Priority
Speaking alongside the president in the White House Rose Garden, Melania Trump described the initiative as a major turning point.
“Beginning today, we will change the reality of women’s health,” she said.
The First Lady outlined five priorities: directing research toward conditions affecting women, using artificial intelligence to accelerate scientific discoveries, bringing new treatments to patients faster, improving affordability and encouraging more open discussions about women’s health.
The administration’s proposed research priorities include menopause, endometriosis, uterine fibroids, infertility, cardiovascular disease, cancer, autoimmune conditions, osteoporosis, Alzheimer’s disease and chronic pain.
Menopause is a particularly significant part of the announcement. Despite affecting a large proportion of women during midlife, its symptoms and longer-term health implications have not always received consistent attention in medical research and clinical care.
Endometriosis, another condition highlighted by the administration, can cause severe pelvic pain, infertility and years of delayed diagnosis.
The White House argues that advances in artificial intelligence, personalized medicine and diagnostic technologies could help address these longstanding gaps.
The broader issue is well established: women have historically been underrepresented in some areas of medical research, and sex-related differences in disease presentation and treatment have not always been adequately studied.
By placing these concerns at the center of a presidential initiative, Melania Trump is giving national visibility to an issue that affects women across political and socioeconomic lines.
What Trump’s New NIH Women’s Health Division Will Actually Do ?
The executive order directs the Department of Health and Human Services to establish a Women’s Health Division within an appropriate NIH institute or center within 90 days.
According to the Department of Health and Human Services, the division will strengthen research on conditions disproportionately affecting women, encourage their inclusion in clinical trials and help translate scientific discoveries into medical practice.
It will also reinforce NIH requirements for researchers to account for sex as a biological variable. The initiative creates a White House Women’s Health Task Force, co-chaired by Health and Human Services Secretary Robert F. Kennedy Jr. and White House Chief of Staff Susie Wiles.
The task force will coordinate federal efforts to improve women’s health across different stages of life, from childhood and adolescence through pregnancy, menopause and aging.
However, the federal government already has an office dedicated to women’s health research.
The NIH Office of Research on Women’s Health was established in 1990. The new division will work alongside that office rather than replace it, according to Reuters.
The distinction matters because the administration is not creating federal women’s health research from scratch. Instead, it is introducing a new structure intended to expand coordination and accelerate the application of research findings.
The White House says its approach will move beyond scientific studies alone to prioritize treatments, prevention and measurable improvements in patient care.
Whether that organizational change produces additional research capacity will depend partly on staffing, funding and implementation.
Why Trump Repealed Biden’s Women’s Health Research Initiatives ?
One of the most consequential provisions of the October 19 executive order is Section 5, which explicitly revokes two Biden administration measures.
The first is a November 2023 presidential memorandum establishing the White House Initiative on Women’s Health Research. The second is a March 2024 executive order intended to advance women’s health research and innovation.
Both were central to a broader initiative championed by former First Lady Jill Biden.
The Biden administration sought to increase research into conditions such as menopause, maternal health, cardiovascular disease and other medical issues that disproportionately affect women.
According to The Associated Press, the previous administration had announced nearly $1 billion in funding connected to its women’s health research strategy.
That figure represented announced or mobilized investments, rather than a guarantee that every dollar had already been spent.
The Trump White House argues that the new order broadens the federal approach by emphasizing the practical application of scientific research.
In its official fact sheet, the administration says it is replacing the earlier initiatives to prioritize turning research into improved clinical care.
That is a substantive policy distinction. Scientific discoveries do not automatically translate into better treatments, and improving the adoption of medical advances is an important public health objective.
But repealing the previous administration’s directives also raises questions about continuity.
The repeal does not automatically terminate every existing grant, research project or funding commitment associated with the Biden initiatives. Those outcomes will depend on subsequent decisions by federal agencies and Congress.
The key question is whether the new framework will preserve, expand or redirect the research already underway.
The Funding Question: An Ambitious Plan Without a New Budget
Despite its broad objectives, Trump’s executive order does not allocate a specific amount of new money to women’s health research.
The text states that the Department of Health and Human Services will cover administrative costs associated with the new task force. Implementation is otherwise subject to available appropriations.
That does not mean the initiative cannot use existing federal research funding or receive future congressional support.
It does mean that the announcement itself does not guarantee additional investment.The funding question is especially important given the broader changes affecting federal research institutions.
The NIH has experienced significant staffing and funding pressures under the Trump administration, according to reporting by The Washington Post and other U.S. news organizations.
Medical research often requires sustained financial support over many years. Clinical trials, specialized laboratories, patient recruitment and long-term studies cannot be expanded through administrative coordination alone.
Women’s health organizations have welcomed the initiative while emphasizing precisely that concern.
In a joint statement issued October 19, the Society for Women’s Health Research, the American College of Obstetricians and Gynecologists and the Women First Research Coalition stressed that sustained investment is essential to improving health outcomes.
“Robust and sustained funding is necessary to meaningfully advance research in women’s health,” the organizations said.
Their broader National Strategy to Close the Women’s Health Gap, supported by nearly 80 national organizations, calls for $20 billion over 10 years across research, regulation, data infrastructure, workforce development and public awareness.
That proposed investment is separate from the Trump administration’s executive order. It illustrates the scale of resources that medical organizations believe will be needed to address longstanding gaps.
The groups’ response is significant because it recognizes the value of the new initiative without treating the announcement itself as proof of future progress.
Abortion Access Remains Outside Trump’s Women’s Health Plan
The executive order describes women’s health as a lifelong priority, covering reproductive years, pregnancy, menopause and aging.
But it does not address abortion restrictions that continue to shape access to reproductive health care in several states.
Since the Supreme Court overturned Roe v. Wade in June 2022, abortion laws have diverged sharply across the country. Some states have enacted strict bans, while others have strengthened protections for abortion access.
The resulting differences have created major disparities in reproductive health services depending on where women live. The Trump administration’s new initiative focuses primarily on medical research, prevention, diagnosis and treatment rather than changing state abortion laws.
Those are distinct areas of public policy, but both affect women’s health outcomes.
Critics of the administration argue that advances in medical research cannot fully address women’s health needs without considering access to reproductive care.
The administration, meanwhile, emphasizes scientific research and the development of better treatments as central to its health agenda.
The disagreement reflects a broader debate over what a comprehensive national women’s health strategy should include.
Why the Announcement Matters Before the 2026 Midterms ?
The political timing is difficult to overlook.
The announcement came just 15 days before the November 3 midterm elections, when voters will decide control of the House of Representatives and more than one-third of the Senate.
Women’s support for President Trump has weakened, according to recent national polling.
A Washington Post–ABC News–Ipsos survey conducted in October found that 30% of women approved of Trump’s performance as president, while 61% said they would prefer Democrats to control Congress.
Those figures reflect the respondents surveyed at that time, not a prediction of how women will vote on Election Day.
Against that backdrop, Melania Trump’s prominent role in a major women’s health announcement is politically notable. The First Lady has generally maintained a selective public profile, making her involvement in developing and presenting this initiative particularly visible.
The policy also addresses issues that cross partisan lines. Menopause, cardiovascular disease, cancer and endometriosis affect millions of American women regardless of political affiliation.
There is no evidence that the initiative was designed solely for electoral purposes. But its timing places women’s health at the center of a national political debate just days before voters head to the polls.
What Will the New Policy Mean for American Women?
Melania Trump’s initiative brings renewed attention to medical conditions that have long been overlooked or insufficiently researched.
Its emphasis on menopause, endometriosis, clinical trials and faster access to treatments addresses genuine gaps in women’s health care.
The administration’s commitment to translating scientific research into practical medical improvements could also prove important if supported by adequate resources.
But the executive order leaves several questions unresolved.
How much additional federal funding, if any, will support the new NIH division? What will happen to programs developed under the Biden administration? And how will the government measure improvements in women’s health outcomes?
Those questions will determine whether the new initiative represents a lasting expansion of women’s health research or primarily a reorganization of existing federal efforts.
For millions of American women, the measure of success will not be the creation of a new task force or which administration receives credit. It will be whether the policy leads to earlier diagnoses, more effective treatments and better access to care.